Every 10-Q that INTENSITY THERAPEUTICS INC (INTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTS filings page.
Intensity Therapeutics, Inc. reported no revenue and continued operating losses for the quarter and six months ended June 30, 2026, reflecting its status as a late-stage clinical biotechnology company. Total assets were $11.5 million, including $9.5 million of cash and cash equivalents, down from $11.9 million at year-end 2025. Net loss was $3.0 million for the quarter and $5.4 million year-to-date, with an accumulated deficit of $83.8 million.
Research and development expenses were $1.8 million for the quarter and $3.0 million year-to-date, as the company funds its INVINCIBLE-3 Phase 3 soft tissue sarcoma study and INVINCIBLE-4 Phase 2 triple-negative breast cancer study. INVINCIBLE-3 enrollment was previously paused for funding reasons but limited U.S. enrollment activities have been restarted under an amended protocol. INVINCIBLE-4 enrollment resumed after a dosing adjustment, supported by preliminary data showing higher pathological complete response rates when INT230-6 is added to standard of care.
The company disclosed that it expects to incur substantial losses for the foreseeable future and stated there is substantial doubt about its ability to continue as a going concern without additional capital. Operations are being financed primarily through equity, including an at-the-market facility under which it has raised $13.1 million to date and can sell up to an additional $58.4 million of common stock.
Intensity Therapeutics, Inc. reported a first‑quarter 2026 net loss of $2.4 million, narrowing from $3.3 million a year earlier, as operating expenses fell to $2.5 million from $3.4 million.
Research and development spending dropped 45% to $1.2 million, mainly from pausing its Phase 3 INVINCIBLE‑3 sarcoma trial and adjusting the INVINCIBLE‑4 breast cancer study. Cash and cash equivalents were $10.2 million as of March 31, 2026, with an accumulated deficit of $80.8 million. The company states there is substantial doubt about its ability to continue as a going concern without additional capital and is relying on equity offerings, including an expanded at‑the‑market program of up to $60.0 million, to fund late‑stage oncology trials.
Intensity Therapeutics (NASDAQ: INTS) filed its Q3 2025 10‑Q, showing lower operating spend and continued reliance on equity financing while advancing its clinical programs. Cash and cash equivalents were $7.1 million as of September 30, 2025, up from $2.6 million at year‑end, driven by an at‑the‑market program and public offerings. Q3 net loss was $2.7 million with operating expenses of $2.7 million as R&D and G&A declined year over year. For the nine months, net loss totaled $8.6 million and operating cash use was $6.8 million.
The company paused enrollment in its Phase 3 INVINCIBLE‑3 sarcoma study in March 2025 due to funding constraints and paused new enrollment in the Phase 2 INVINCIBLE‑4 TNBC study in September 2025 to revise dosing. Subsequent to quarter‑end, INTS raised $2.0 million net via ATM and $4.0 million gross in a registered direct offering. Management states available capital is expected to fund current operations until the end of the first quarter of 2027, yet the filing notes substantial doubt about continuing as a going concern given the need for additional financing. Shares outstanding were 49,068,621 as of September 30, 2025; 60,064,965 as of November 5, 2025.
Intensity Therapeutics (INTS) filed its Q2-25 10-Q showing sharply lower spending but continued losses. R&D expense fell 57% YoY to $1.5 M and G&A fell 23% to $1.2 M, trimming the quarterly net loss to $2.5 M (-$0.13/sh) from $5.0 M (-$0.36/sh) a year ago. For the six-month period, the net loss was $5.9 M (-$0.35/sh) versus $9.6 M in 1H-24.
Liquidity. Cash & equivalents were $2.2 M on 30 Jun 25, down $0.4 M from year-end. Subsequent ATM sales added $6.6 M, and combined April and June public offerings plus Q2 ATM activity brought in $4.1 M during the quarter. Management believes cash now extends into 2H-26, yet the filing still cites substantial doubt about going-concern status.
Clinical pipeline. • Phase 3 INVINCIBLE-3 (sarcoma) enrollment paused in March due to funding; 23 patients accrued, treatment continues. • Phase 2 INVINCIBLE-4 (TNBC) ongoing with target completion 1H-26 subject to financing. • Phase 1/2 IT-01 and Phase 2 INVINCIBLE-2 completed.
Capital structure. Share count rose to 26.2 M from 15.1 M at YE-24 through offerings and ESPP issuances; APIC stands at $74.8 M, while the accumulated deficit reached $72.7 M.
Nasdaq compliance. The company believes recent equity raises restored the minimum $2.5 M shareholders’ equity requirement but still faces $1.00 bid-price deficiency.